Page 9 - SaxoCell Annual Report 2021

from our Core Institutions

With the SaxoCell future cluster, we are creating an internationally
visible beacon for cell and gene therapy in Saxony. Together with
our partners, we are strengthening the innovative cell and gene
therapy industry, closing gaps in the value chains and leveraging
synergy potential - for pioneering medicine made in Germany. This
not only strengthens the region of Saxony, but will also create new
therapeutic options for patients, for example in tumor diseases or
autoimmune diseases.
Prof. Dr.-Ing. habil. Reimund Neugebauer Welcome
President of the Fraunhofer-Gesellschaft
Photo copyright © Fraunhofer / T. Dashuber

SaxoCell is a milestone in medical care in Saxony. With its
participation, Chemnitz Hospital will make a decisive contribution
to the development of novel drugs in the promising field of cell
and gene therapy. Together with our partners, we are transferring
modern research findings into clinical application in order to be
able to treat diseases that are incurable today in the future.

Dipl.-Oec. Dirk Balster
Managing Director Klinikum Chemnitz gGmbH

4